SureNano Science Ltd. ($SURE) is thrilled to announce the completion of its acquisition of GlucaPharm Inc., a pioneering pharmaceutical company focused on developing GEP44, a patented peptide aimed at combating obesity and metabolic disorders. This innovative therapy is designed to deliver improved tolerability and delivery potential compared to existing options like Ozempic®, Wegovy®, and Mounjaro®.
Located in Vancouver, British Columbia, SureNano's acquisition of GlucaPharm represents a strategic shift from an enabling-technology entity to a near-term pharmaceutical innovator within one of the fastest-growing global drug markets. GEP44 aligns seamlessly with SureNano's mission to enhance the performance and patient experience of advanced therapeutics.
The acquisition was structured as a share exchange, with SureNano issuing a total of 8,100,999 common shares to GlucaPharm shareholders, along with warrants for an additional 5,000,000 shares, as detailed in a previous press release dated November 19, 2025. These shares will be subject to specific hold periods pending regulatory approvals.
SureNano also announced the appointment of Dr. Nihar R. Pandey as Director and Chief Scientific Officer. Dr. Pandey brings over 25 years of biochemistry and clinical research experience, having developed numerous IP-protected drug formulations and led major advancements in research and regulatory compliance.
GEP44, discovered by researchers at Syracuse University, demonstrates significant weight loss and blood glucose normalization in preclinical studies, without the common gastrointestinal side effects of other GLP-1 drugs. The peptide is exclusively licensed from Syracuse University and seeks to provide better patient tolerability while targeting comparable, if not superior, efficacy.
The global GLP-1 market, still in its early stages, is primarily dominated by injectable therapies such as Ozempic® and Mounjaro®, which have seen substantial revenues and market adoption. GlucaPharm aims to differentiate itself by advancing non-injectable administration methods, such as oral, sublingual, or nasal delivery, potentially expanding patient adoption and market penetration.
With the assistance of an experienced Australian contract research organization (CRO), GlucaPharm is set to initiate an IND-enabling FDA study followed by a Phase I Clinical Trial in Australia. Significant development milestones are expected in the next six to nine months, including IND progression and early clinical validation.
Charles MaLette, CEO of SureNano, emphasized the transformative nature of this acquisition, stating, "GlucaPharm provides the Company with a highly differentiated GLP asset at a time when demand for effective, better-tolerated metabolic therapies continues to accelerate globally." He highlighted the experienced development team and strong institutional support backing GEP44, positioning SureNano as a key player in the burgeoning pharmaceutical market.
Recently, SureNano secured $1.25 million in financing, including warrants exercisable at $0.35, to support immediate development efforts and future funding rounds. As GEP44 progresses through its regulatory phases towards FDA approval, the combined company is poised to become one of the few micro-cap public entities engaged in GLP technology, targeting a multi-hundred-billion-dollar market.
For more information about SureNano and its initiatives, visit insideticker.com/ticker/surenano.